Correction to: Comparative efficacy safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis

摘要

Efficacy Results. a VS Risk Difference (RE model). b CD4 difference (FE model)